Figure 7. Constitutive PDGFRα activation leads to pulmonary hypertension.

A, Timeline of tamoxifen (Tam) induction and analysis of PW1^nLacz/PDGFRα^+/(S)K/Rosa‐CRE⁺ mice. B to E, Analysis of mice 5 weeks after tamoxifen induction. B and D, Right ventricular systolic pressure (RVSP) was measured in control or tamoxifen‐treated (B), males (n=7–10) and (D), females (n=5–6). C and E, Right ventricular hypertrophy was determined using the Fulton index (right ventricular weight to left ventricular+septum weight ratio) in control or tamoxifen‐treated (C), males (n=5–6) and (E), females (n=5–6). F, Timeline of PDGF‐AA treatment and analysis of PW1nLacz⁺ mice. G through J, Analysis of mice after 5 weeks of PDGF‐AA treatment. G and I, Right RVSP was measured in control or PDGF‐AA‐treated (G), males (n=5–6) and (I), females (n=5–6). H and J, Right ventricular hypertrophy was determined using the Fulton index in control or PDGF‐AA–treated (H), males (n=5–6) and (J), females (n=5–6). Bars represent means and whiskers represent SD. *P<0.05, **P<0.01; ns indicates not significant (2‐tailed Mann‐Whitney); PDGF, platelet‐derived growth factor; PDGFRα, platelet‐derived growth factor receptor type α; and PW1, protein widely 1.